Mesoblast Limited
NASDAQ:MESOBiotechnology
+$0.26 today
- Market cap
- $1.51B
- Beta
- 0.79
- P/E (TTM)
- -23.6
- EPS (TTM)
- -$0.06
Volume 0.13M
Average 0.21M
MESO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Mesoblast LimitedNASDAQ: MESO
Cost of Revenue · Q4 FY2026 · quarter ended Jun 2026
Cost of revenue turns negative
Q4 FY2026 cost of revenue was -$49.42M, compared with $23.25M a year earlier. Trailing-twelve-month cost of revenue was $19.21M. Over 3 fiscal years it compounded at -29.5% a year.
Context
- Cost of revenue amounted to 15.9% of revenue in FY2026, down 13.9 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near -$49.42M or moves back toward the trailing-twelve-month quarterly average of $4.8M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2026
- 19.21M USD
- Year-over-year change
- +274.5%
- 4-year CAGR
- -25.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 19.21M | +274.5% |
| FY2025 | 2025-06-30 | 5.13M | -87.5% |
| FY2024 | 2024-06-30 | 41.07M | -25.2% |
| FY2023 | 2023-06-30 | 54.92M | -13.6% |
| FY2022 | 2022-06-30 | 63.57M | — |
Cost of Revenue vs competitors
How MESO compares with its peers on the latest reported figures
- MESO's LTM Jun 2026 cost of revenue of $19.21M is the 4th highest of the 6 companies compared; the peer median is $32.58M.
- Its year-over-year change of -63.8% is the lowest of 6, against a peer median of -26.6%.
- Cost of revenue amounts to 16.0% of revenue for MESO, versus a peer median of 33.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.36M | +63.0% | +84.1% | 43.0% | |
| LTM Mar 2026 | $42.41M | -26.6% | — | — | |
| LTM Mar 2026 | $32.58M | -62.0% | -2.1% | 515.8% | |
| LTM Jun 2026 | $19.21M | -63.8% | -29.5% | 16.0% | |
| LTM Dec 2025 | $6.36M | -57.6% | -31.4% | 24.0% | |
| LTM Mar 2026 | $298K | +9.6% | +5.1% | 2.0% | |
| Peer median (excluding MESO) | $32.58M | -26.6% | +1.5% | 33.5% | |
Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 10.21M | 7.5M | 5.9M | 17.2M | 120.79M |
| Cost of Revenue | 63.57M | 54.92M | 41.07M | 5.13M | 19.21M |
| Gross Profit | (53.36M) | (47.42M) | (35.17M) | 12.07M | 101.58M |
| Gross Margin | -522.6% | -632.2% | -595.9% | 70.2% | 84.1% |
| Research & Development | 32.82M | 27.19M | 25.35M | 34.81M | 97.94M |
| Selling, General & Admin | 57.97M | 53.11M | 23.63M | 39.31M | 55.13M |
| Operating Expenses | 90.79M | 76.79M | 48.98M | 74.51M | 153.08M |
| Depreciation & Amortization | 4.38M | 4.11M | 1.9M | 6.4M | 8.62M |
| EBITDA | (76.57M) | (58.55M) | (56.08M) | (73.66M) | (42.88M) |
| EBITDA Margin | -749.9% | -780.6% | -950.1% | -428.3% | -35.5% |
| Operating Income | (80.57M) | (69.29M) | (84.15M) | (62.44M) | (51.5M) |
| Operating Margin | -789.1% | -923.7% | -1425.7% | -363.1% | -42.6% |
| Interest Income | 0 | 831K | 1.82M | 3.55M | 3.93M |
| Interest Expense | 17.29M | 19.44M | 20.66M | 22.93M | 23.95M |
| Other Income / Expenses | (10.48M) | (12.81M) | (4M) | (39.37M) | (5.64M) |
| Income Before Tax | (91.59M) | (82.1M) | (88.15M) | (101.81M) | (57.14M) |
| Pre-Tax Margin | -896.9% | -1094.5% | -1493.5% | -592.0% | -47.3% |
| Income Tax Expense | (239K) | (212K) | (191K) | 330K | 615.74K |
| Net Income | (91.35M) | (81.89M) | (87.96M) | (102.14M) | (57.76M) |
| Net Margin | -894.6% | -1091.7% | -1490.3% | -593.9% | -47.8% |
| EPS (Basic) | (1.30) | (0.98) | (0.89) | (0.84) | (0.45) |
| EPS (Diluted) | (1.30) | (0.98) | (0.89) | (0.84) | (0.45) |
| Weighted Avg Shares | 68.27M | 83.77M | 98.67M | 120.78M | 129.49M |
| Weighted Avg Shares (Diluted) | 68.29M | 83.93M | 98.67M | 120.78M | 129.49M |
Mesoblast Limited
NASDAQ:MESO
Intrinsic Alpha fair value
Locked
Current Price
$11.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.